Loncar Cancer Immunotherapy ETF (CNCR)
|Ex-Dividend Date||Dec 30, 2020|
|Day's Range||31.26 - 31.41|
|Inception Date||Oct 13, 2015|
The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.
Top 10 Holdings42.34% of assets
|Trillium Therapeutics Inc||TRIL.TO||6.08%|
|ALX Oncology Holdings||ALXO||4.13%|
|Dec 30, 2020||$0.2881193||Jan 4, 2021|
|Dec 28, 2017||$0.35019938||Jan 2, 2018|
|Dec 29, 2015||$0.10551286||Jan 4, 2016|
Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new fun...
Both stock index ETFs and biotech stocks and ETFs have been on a tear lately thanks to promising coronavirus vaccine developments from several major pharmaceutical companies. But this week, the U.K. bec...
Healthcare stocks and ETFs are continuing to outperform as investors are optimistic about an upcoming vaccine for the coronavirus, which has been a blight on the globe since early this year. There has b...
We have highlighted ETFs that were at the forefront of the market rebound on Sep 9 and will continue to do so if market sentiments remain positive.
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Stock indexes and ETFs rocketed higher and are continuing the uptrend in trading Wednesday after Moderna said its coronavirus vaccine generated antibodies in elderly patients for the first time, creatin...
Stock futures rocketed higher and are continuing the uptrend in overnight trading on Tuesday after Moderna said its coronavirus vaccine generated antibodies in all patients in an early trial, creating o...
With the race to find a vaccine for the coronavirus, now drugmaker AstraZeneca is the latest to receive funding to generate a panacea.
U.S. stocks are continuing to soar higher on Monday, moving into positive territory for May, following news that drugmaker Moderna released positive, preliminary results from the first human trial of it...
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.